President Donald Trump signed an executive order on April 18, 2026, to fast‑track federal research on the psychedelic drug ibogaine for U.S. veterans with PTSD[1].
The move matters because nearly one‑third of U.S. veterans experience PTSD, and existing therapies leave many without relief. Accelerating research could bring a new option to a population that has long struggled for effective care[2].
Ibogaine, a plant‑derived alkaloid traditionally used in West Africa, has shown promise in early studies for reducing trauma‑related symptoms, but it remains a Schedule I substance in the U.S. and has not been widely tested in clinical trials[2].
The order directs the Department of Health and Human Services, in coordination with the National Institutes of Health, to prioritize grant applications, streamline Institutional Review Board approvals, and report progress to the White House every six months—an effort intended to cut years off the typical research timeline[3].
Reports differ on the order’s exact status. The New York Post said Trump signed the order on April 18[1]. CBS News said the president "is to sign" the measure, implying it had not yet been executed[2]. CNN said the signing was expected on April 16, 2026[3]. The discrepancy highlights the fast‑moving nature of the announcement and the reliance on varying news cycles.
If the order proceeds as outlined, federal funding for ibogaine studies could increase dramatically, allowing multi‑site trials that assess safety, dosage, and therapeutic efficacy. Successful results might pave the way for an FDA‑approved indication, offering veterans a novel treatment pathway.
Experts caution that accelerated timelines must still meet rigorous safety standards. The Drug Enforcement Administration will retain oversight of any clinical use, and the order does not alter the requirement for FDA approval before ibogaine can be prescribed broadly[2].
“The order aims to accelerate ibogaine trials for veterans with PTSD.”
If implemented, the executive order could shorten the path from laboratory to clinic for ibogaine, potentially delivering a new therapeutic option for veterans with PTSD. However, the variation in reporting underscores the need for clear, official confirmation and careful oversight to ensure safety and scientific rigor.
